S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

NCT01693419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Pancreas Neoplasms

Interventions

DRUG: GES (Gemcitabine, Erlotinib, S-1)

Sponsor

Hallym University Medical Center

Collaborators

[object Object]